BOSTON SCIENTIFIC CORP — Form 8-K
Filed November 17, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 18/100
What the filing says
Boston Scientific filed three new compensation plans effective 2027: (1) Annual Bonus Plan tied to Global Sales, Adjusted EPS, and quality goals with 0–150% payout range; (2) Relative TSR Program measuring stock performance vs. S&P 500 Healthcare Index (60 companies) over 2027–2029 with 0–200% vesting; (3) Organic Net Sales Growth Program measuring 2027–2029 organic growth with 0–200% vesting. All are standard executive incentive structures with no dollar amounts or share counts specified in the filing; actual awards determined by Committee at grant.
Why this rating
Routine disclosure of annual incentive plan templates. No material change to business, no specific grants, no dollar impact quantified. Standard governance housekeeping for $158.7B company.
See more from November 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.